Nuvilex, Inc. Diabetes Studies Could Eliminate Need for Daily Insulin Requirements

NEW YORK, NY--(Marketwire - Mar 18, 2013) - When investors look into biotechnology and pharmaceutical companies as an investment opportunity, three areas of research stand out as the most favorable for future returns. The big three are cancer, heart disease and diabetes research that can eventually lead to corresponding clinical trials. Well, Nuvilex, Inc. (OTCQB: NVLX) is currently involved in 2 of the 3 -- cancer and diabetes.

While Nuvilex prepares for a large-scale, late-phase clinical trial studying its treatment for patients with advanced, inoperable pancreatic cancer, the company is also using the same basic technology to study diabetes. That technology is a unique and proprietary living cell encapsulation process, and the good news for those with diabetes is the basic technology has delivered astounding results in the company's pancreatic cancer trials. 

By 2020, the market for diabetes medicines is projected to reach $65 billion worldwide. According to the International Diabetes Federation, 371 million people around the world have been diagnosed with diabetes and another 187 million remain undiagnosed -- leaving many millions susceptible to the debilitating, and even deadly, complications associated with this disease. 

If left untreated, complications from diabetes can include; heart disease, vision loss, kidney disease, and nerve damage. Diabetes is characterized by sustained high levels of sugar (glucose) in the blood. Glucose is a source of energy for all cells in the body, and the levels of glucose are regulated by insulin which is produced by islet cells within the pancreas.

Researchers are putting their focus squarely on those islet cells as they are the key to what can only be described as miracle science at Nuvilex. The company is doing some amazing things with its living cell encapsulation technology that could make life much simpler for those who suffer from diabetes.

Continue reading and discover how Nuvilex, Inc. is creating a type of "Artificial Pancreas" at www.stockhousegroup.com/features

About Stock House Group

Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform to CEO's to develop their story through the press, Research Reports, and CEO Interviews. At the same time, we're building a library of Research to assist Investors in their due diligence on micro, small and large cap stocks.